ESMO Media Releases

We are pleased to announce that the ESMO 2018 Annual Congress will take place between 19-23 October 2018 at the Messe Muenchen, Germany

The lively discussion which followed the presentation of ‘A pivotal phase 3 Trial of MABp1 in advanced colorectal cancer'

Details of the first study by one of Europe’s largest cancer centres, the Medical University of Vienna (MUV), assessing the clinical impact and feasibility of the ESMO Magnitude of Clinical Benefit Scale (MCBS) in a real-life context are now available on ESMO Open

Guidelines reflect personalised treatment approach

AIOM adopts ESMO Open as its scientific journal

Phase III trial finds excellent safety and tolerability

Phase III trial confirms efficacy and safety of new second-line agent

Phase III trial finds no significant difference in overall survival

Phase I trial achieves partial responses and is well tolerated

The European Medicines Agency (EMA) and the European Society for Medical Oncology (ESMO) will host a workshop on single-arm trials (SATs) at the EMA headquarters in London, UK, on June 30th 2016.

A total of 15 oncologists from 12 European countries* have been chosen to participate in the first ESMO Leaders Generation Programme designed to develop the careers of oncology’s future leaders.

Nearly 2,900 abstracts were submitted for inclusion within the ESMO 2016 Congress, marking a 70% increase over the past six years and confirming the ESMO Congress as the leading oncology event in Europe...